×

Nano Labs Develops Diagnostic Technology to Identify Tuberculosis (TB) Through Novel Nanotechnologies

Nano Labs Corp. Logo

DETROIT, March 4, 2013 (GLOBE NEWSWIRE) -- Nano Labs Corp. (OTCQB:CTLE) is pleased to present industry with promising biological diagnostics test results obtained at macro-level, on a miniaturized tuberculosis biosensor platform.

The Company successfully developed a Point-of-Care biosensor at macro-level and presents industry with proposals for miniaturization and commercialization at large scale. The joint venture proposal is for the development of miniaturized Point-of-Care (PoC) and Lab-on-Chip (LoC) biosensors.

The Company reports that four innovative solutions are proposed with the main objective to create a simple, low-cost, high-sensitivity, rapid diagnostic platform capable of being used in remote locations for PoC and LoC monitoring of critical infectious diseases, including tuberculosis (TB).

The Company's aim is to establish a commercial PoC and LoC biosensors using modern techniques by either applying common Micro-Electro-Mechanical-Systems (MEMS) batch processes, or by using simpler and more modular methods such as soft lithography or laser ablation. According to the Company report, four (4) possible innovative solutions combining biomarker-based diagnostics procedures with micro-technology have been identified:

1. Quantum-Dots Microchannels (QDμC)

2. Surface Plasmon Resonance (SPR) Spectroscopy & Plasmonic Enzyme-Linked Immuno Sorbent Assay (Plasmonic ELISA)

3. Micro Electrochemical Impedance Spectroscopy (μEIS)

4. Surface Acoustic Wave Micro-Electro-Mechanical-System (SAW-MEMS).

"It is important to note that innovative, comprehensive strategies for obtaining a functional prototype will need to be carefully addressed for all projects, at any development stage," adds Dr. Victor Castano, Chief Research and Innovation Officer at Nano Labs. "This includes packaging, interconnect with outside world, and modular integration on circuits or with some sort of display."

The Company is in discussions with industry leaders to assess product development strategies and additional research required over the next twelve months to advance the commercialization of the product.

"We are looking at partnerships that bring the experience, dedication and the vision to address critical world health issues, like tuberculosis," stated Mr. Bernardo Chavarria, President of Nano Labs. "We expect that new research areas and biosensor solutions will emerge from this project and therefore present a much larger scope of practical applications that need to be further investigated. This technology has enormous potential and will bring exciting new opportunities to our company."

About Nano Labs

Nano Labs Corp. (CTLE) is a nanotechnology company which began during October 2012, but is able to access resources that encompass nearly 30 years of research and development in nanotechnology as well as hundreds of peer-reviewed and published research papers and other scholarly material. The Company's research and development team of scientists, designers, and engineers is focused on creating a portfolio of advanced products that could provide benefits to a variety of industries including: (i) consumer products, (ii) energy, (iii) materials, and (iv) healthcare. Through the use and integration of proprietary nano compounds, our goal is to evolve common products into new, revolutionary products in order to make the world a better place. Nano Labs shares are traded on the OTC Bulletin Board in the United States under the ticker CTLE. For more information, please visit www.NanoLabs.us.

The Nano Labs Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16293

Forward looking statements

This press release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those laws. These forward-looking statements are based upon a number of assumptions and estimates that are subject to significant uncertainties that involve known and unknown risks, many of which are beyond our control and are not guarantees of future performance. Actual outcomes and results could materially differ from what is expressed, implied, or forecasted in any such forward-looking statements and any such difference may be caused by risk factors listed from time to time in the Company's news releases and/or its filings with the OTC Bulletin Board or as a result of other factors.

CONTACT: Nano Labs Corp. Bernardo Camacho Chavarria President 1 (888) 806-2315

Source:Nano Labs Corp.

More From Press Releases